Justice Nicholas Oweibo of the Federal High Court, sitting in Lagos, south west Nigeria has set aside an order obtained by a liability company, Duport Energy Limited over the control of a leading energy developing company Duport Midstream Company Limited
Share this article
Share this article
PLANO, Texas, Dec. 29, 2020 /PRNewswire/ U.S. Renal Care (USRC), a leading provider of dialysis services caring for more than 26,000 individuals living with kidney disease, announced it will obtain and distribute the monoclonal antibody therapy, Bamlanivimab, to its patients recently diagnosed with COVID-19. USRC obtained the therapy from Operation Warp Speed, Project SPEED, and will administer the drug to medically stable COVID-19 positive patients with mild to moderate disease in their outpatient dialysis facilities. USRC is among the first national dialysis organizations to offer this therapy. Our internal data is consistent with data from CMS that demonstrates extraordinarily high rates of hospitalization for Medicare beneficiaries with end-stage kidney disease who contract COVID-19, said Mary Dittrich, MD, FASN, Chief Medical Officer, USRC. Having the ability to administer monoclonal antibody therapy to high-risk, COVID-19 positive